Back

A Phase I/II Study of TTI-622 in Combination with Pegylated Liposomal Doxorubicin in Patients with Platinum-Resistant Ovarian Cancer

A Phase I/II Study of TTI-622 in Combination with Pegylated Liposomal Doxorubicin in Patients with Platinum-Resistant Ovarian Cancer

  • Clinical Trial Information

    Trial Contact: Donaldson, Karin M; Grofsik, Kiera; Frankos, Marie; Djuro, Victor; Walton, Sherri

  • IRB No: 22.031.02

    Protocol Abbrev: TTI-622-02

    Principal Investigator: Shelly Marie Seward, MD

    Phase: Drug: Phase I

    Age Group: Adult

    Secondary Protocol No: C4971002, Trillium ZZA82397

    Treatment: TTI-622 (SIRPĪ±-IgG4 Fc)

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT05261490

  • Objective

    Primary Objectives:
    1. Evaluate the safety of escalating dose levels of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles and establish the MTD and/or RP2D combination
    regimen (Phase I portion of study)

    2. Gain a preliminary assessment of clinical activy of TTI-622 in combination with 40 mg/m2 PLD (Phase II portion of study)